U.S. market Closed. Opens in 7 hours 46 minutes

VRTX | Vertex Pharmaceuticals Incorporated Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for VRTX we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is very good and Health is weak.

Valuation (36%)

Company Industry
P/E Ratio (TTM) -219.49 -18.09
PEG Ratio (TTM) -103.71 -5.18
P/S Ratio (TTM) 9.91 52.20
P/B Ratio (TTM) 6.74 28.91
P/FCF Ratio (TTM) -90.32 -7.12
Price to 5YR AVG Earnings Ratio 39.92 -7.20
Price to 5YR AVG FCF Ratio 37.28 -13.31

Profitability (25%)

Company Industry
ROA (TTM) -2.16% -16.66%
ROE (TTM) -2.89% 27.93%
Net Profit Margin (TTM) -4.52% -796.50%
ROIC 5YR AVG 68.11% -20.53%

Growth (80%)

4QTR AVG 3YR AVG 5YR AVG
EPS -72.65% 23.51% 24.31%
Revenue 2.84% 35.91% 27.23%
Net Income -72.66% 24.31% 24.74%
Cash Flow 31.16% 37.37% 30.80%

Health (49%)

Company Industry
Current Ratio (TTM) 2.47 5.80
Quick Ratio (TTM) 2.20 5.58
D/E Ratio (TTM) N/A 0.97
Interest Coverage (TTM) -8.18 -7.65
Piotroski F-Score 3 5
Altman Z-Score 10.93 13.09
LTL to 5YR AVG FCF 0.51 0.07
Shares Outstanding Growth 5YR AVG 0.27% 40.92%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙